Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. AstraZeneca, Daiichi Sankyo and Gilead have made big advances in treating the hardest-to-tackle type of ...

Reports from CNBC-TV18, quoting sources, indicate that Fettle Tone and Krishnan Ramchandra are likely to sell up to 7.2% of their stake in Niva Bupa Health Insurance Company through block deals. The ...

The Key Dyslipidemia Companies in the market include - Merck Group, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol Myers Squibb, Cipla, CKD Bio Corporation, AstraZeneca, ...

Relay Therapeutics has beaten its survival goal in a first-in-human breast cancer study, positioning the biotech to move into a pivotal trial that could establish its candidate as a challenger to ...

WILMINGTON, Del.--(BUSINESS WIRE)--The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of ...

The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease with a broad range of blood eosinophil counts and irrespective of ...

Alpha-1 Antitrypsin Deficiency (AATD) is a hereditary autosomal codominant genetic disorder characterized by a shortage of the alpha-1 antitrypsin protein (AAT). This protein is crucial for ...

A spectacular mosaic art installation created from more than 1,000 images by schoolchildren has been unveiled at the UK’s largest laboratory - AstraZeneca’s Discovery Centre in Cambridge. Years in the ...

New administration option for first and only severe asthma biologic approved in the EU with no phenotype or biomarker limitations AstraZeneca’s Tezspire (tezepelumab) has received a positive opinion ...